The Association Between Higher Expression of Talin-1 and the Reduced Survival Rate in Ovarian Serous Carcinoma Patients.
Cancer progression
Ovarian serous carcinoma
Prognosis
Talin-1
Tissue microarray
Journal
Iranian journal of pathology
ISSN: 1735-5303
Titre abrégé: Iran J Pathol
Pays: Iran
ID NLM: 101515128
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
05
2022
accepted:
28
01
2023
medline:
9
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
ppublish
Résumé
Talin-1 is a constituent of the multiprotein adhesion complexes that play main role in the formation of tumors and migration in different types of malignancies. The present study aimed to assess expression and prognostic significance of the talin-1 protein in ovarian serous carcinoma (OSC) patients. The expression of talin-1 in mRNA and its protein levels were investigated for ovarian cancer (OC) by using bioinformatics tools, including Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Gene Expression Database of Normal and Tumor Tissue 2 (GENT2), and The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) databases. Thereafter, immunohistochemical (IHC) staining was used to study the expression patterns of the talin-1 protein using 46 paraffin-embedded OSC tissue specimens, 25 benign tumors, and 20 normal tissues, which were assembled in tissue microarrays (TMAs). We also assessed the potential association between the expression of the talin-1 protein, various clinicopathological parameters, and survival outcomes. Our IHC examination for talin-1 was significantly overexpressed in OSC tissues compared to benign tumors and normal tissues. The Kaplan-Meier survival analysis has also indicated statistically significant differences in terms of disease-specific survival (DSS) and progression-free survival (PFS) between the patients with high and low expression levels of talin-1, respectively. The talin-1 protein was overexpressed in OSC tissues, and a high expression level of talin-1 was found to be significantly associated with tumor aggressiveness and poorer DSS or PFS. Therefore, talin-1 may serve as a molecular marker of cancer progression and a novel prognostic biomarker in these patients.
Sections du résumé
Background & Objective
UNASSIGNED
Talin-1 is a constituent of the multiprotein adhesion complexes that play main role in the formation of tumors and migration in different types of malignancies. The present study aimed to assess expression and prognostic significance of the talin-1 protein in ovarian serous carcinoma (OSC) patients.
Methods
UNASSIGNED
The expression of talin-1 in mRNA and its protein levels were investigated for ovarian cancer (OC) by using bioinformatics tools, including Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Gene Expression Database of Normal and Tumor Tissue 2 (GENT2), and The University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) databases. Thereafter, immunohistochemical (IHC) staining was used to study the expression patterns of the talin-1 protein using 46 paraffin-embedded OSC tissue specimens, 25 benign tumors, and 20 normal tissues, which were assembled in tissue microarrays (TMAs). We also assessed the potential association between the expression of the talin-1 protein, various clinicopathological parameters, and survival outcomes.
Results
UNASSIGNED
Our IHC examination for talin-1 was significantly overexpressed in OSC tissues compared to benign tumors and normal tissues. The Kaplan-Meier survival analysis has also indicated statistically significant differences in terms of disease-specific survival (DSS) and progression-free survival (PFS) between the patients with high and low expression levels of talin-1, respectively.
Conclusion
UNASSIGNED
The talin-1 protein was overexpressed in OSC tissues, and a high expression level of talin-1 was found to be significantly associated with tumor aggressiveness and poorer DSS or PFS. Therefore, talin-1 may serve as a molecular marker of cancer progression and a novel prognostic biomarker in these patients.
Identifiants
pubmed: 37942198
doi: 10.30699/IJP.2023.554227.2901
pmc: PMC10628370
doi:
Types de publication
Journal Article
Langues
eng
Pagination
312-326Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Medicine (Baltimore). 2016 Jul;95(29):e4326
pubmed: 27442684
Oncology. 2011;80(5-6):406-15
pubmed: 21846996
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Int J Mol Med. 2013 Aug;32(2):381-8
pubmed: 23722670
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:2-3
pubmed: 30306587
Eur Rev Med Pharmacol Sci. 2014;18(17):2533-7
pubmed: 25268101
Am J Obstet Gynecol. 2015 Sep;213(3):262-7
pubmed: 25818671
Int Rev Cell Mol Biol. 2011;289:117-47
pubmed: 21749900
Asian Pac J Cancer Prev. 2011;12(12):3265-9
pubmed: 22471464
Curr Drug Metab. 2020;21(1):25-32
pubmed: 32056520
Neoplasia. 2022 Mar;25:18-27
pubmed: 35078134
World J Transl Med. 2014 Apr 12;3(1):1-8
pubmed: 25525571
PLoS One. 2020 Aug 25;15(8):e0238103
pubmed: 32841288
Sci Rep. 2020 Oct 20;10(1):17786
pubmed: 33082414
Oncol Lett. 2019 Nov;18(5):5408-5416
pubmed: 31612049
Pathol Oncol Res. 2017 Oct;23(4):793-802
pubmed: 28083789
Appl Immunohistochem Mol Morphol. 2017 Sep;25(8):592-598
pubmed: 26894647
Heliyon. 2019 Dec 05;5(12):e02826
pubmed: 31867451
J Oncol. 2011;2011:475983
pubmed: 21577260
Int J Biol Markers. 2016 Feb 29;31(1):e53-61
pubmed: 26391478
Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):170-4
pubmed: 17525629
Cancers (Basel). 2022 Jan 14;14(2):
pubmed: 35053578
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
J Cell Sci. 2017 Aug 1;130(15):2435-2446
pubmed: 28701514
Cancer Med. 2019 Nov;8(16):7018-7031
pubmed: 31560828
CA Cancer J Clin. 2020 Jul;70(4):245-271
pubmed: 32515498
Cancer. 2003 Sep 1;98(5):908-17
pubmed: 12942556
Front Oncol. 2020 Feb 05;10:68
pubmed: 32117725
BMC Med Genomics. 2019 Jul 11;12(Suppl 5):101
pubmed: 31296229
Asian Pac J Cancer Prev. 2012;13(6):2973-8
pubmed: 22938492
Cancers (Basel). 2018 Nov 12;10(11):
pubmed: 30424539
J Pathol. 2011 Jul;224(3):367-76
pubmed: 21547905
Lab Invest. 2000 Dec;80(12):1943-9
pubmed: 11140706
BMC Cancer. 2015 Apr 30;15:332
pubmed: 25925041